{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:59:23Z","timestamp":1791932363076,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"45","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.vaccine.2020.08.001","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T03:24:37Z","timestamp":1600399477000},"page":"7166-7174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Characterization of rVSV\u0394G-ZEBOV-GP glycoproteins using automated capillary western blotting"],"prefix":"10.1016","volume":"38","author":[{"given":"Kevin","family":"Minsker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard R.","family":"Rustandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Loughney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.08.001_b0005","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.idc.2019.08.005","article-title":"Ebola virus disease epidemiology, clinical features, management, and prevention","volume":"33","author":"Nicastri","year":"2019","journal-title":"Infect Dis Clin N Am"},{"issue":"1","key":"10.1016\/j.vaccine.2020.08.001_b0010","first-page":"81","article-title":"An overview of Ebola virus disease","volume":"2","author":"Kadanali","year":"2015","journal-title":"North Clin Istambul"},{"key":"10.1016\/j.vaccine.2020.08.001_b0015","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1056\/NEJMsr1513109","article-title":"After Ebola in West Africa \u2013 unpredictable risks, preventable epidemics","volume":"375","author":"WHO Ebola Response Team","year":"2016","journal-title":"N Eng J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2020.08.001_b0020","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1128\/JVI.02190-10","article-title":"A new Ebola virus nonstructural glycoprotein expressed through RNA editing","volume":"85","author":"Mehedi","year":"2011","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2020.08.001_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1003258","article-title":"The secret life of viral glycoproteins: moonlighting in immune evasion","volume":"9","author":"Cook","year":"2013","journal-title":"Plos Path"},{"issue":"7201","key":"10.1016\/j.vaccine.2020.08.001_b0030","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature07082","article-title":"Structure of the Ebola virus glycoprotein bound to a human survivor antibody","volume":"454","author":"Lee","year":"2008","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.vaccine.2020.08.001_b0035","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2217\/fvl.09.56","article-title":"Ebolavirus glycoprotein structure and mechanism of entry","volume":"4","author":"Lee","year":"2009","journal-title":"Future Virol"},{"key":"10.1016\/j.vaccine.2020.08.001_b0040","first-page":"1","article-title":"Ebola virus entry: a curious and complex series of events","volume":"30","author":"Mollar-Tank","year":"2015","journal-title":"Plos Path"},{"key":"10.1016\/j.vaccine.2020.08.001_b0045","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/cbic.200600223","article-title":"Structure-function analysis of the soluble glycoprotein, sGP, of ebola virus","volume":"7","author":"Falzarano","year":"2006","journal-title":"ChemBioChem"},{"key":"10.1016\/j.vaccine.2020.08.001_b0050","doi-asserted-by":"crossref","first-page":"5762","DOI":"10.1073\/pnas.95.10.5762","article-title":"Processing of the Ebola virus glycoprotein by the proprotein convertase furin","volume":"95","author":"Volchkov","year":"1998","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"10.1016\/j.vaccine.2020.08.001_b0055","doi-asserted-by":"crossref","first-page":"e00862","DOI":"10.1128\/mBio.00862-13","article-title":"Comprehensive functional analysis of N-linked glycans on Ebola virus GP1","volume":"5","author":"Lennemann","year":"2014","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2020.08.001_b0060","doi-asserted-by":"crossref","first-page":"12463","DOI":"10.1128\/JVI.76.24.12463-12472.2002","article-title":"Covalent modifications of the ebola virus glycoprotein","volume":"76","author":"Jeffers","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.08.001_b0065","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/rcm.4410","article-title":"Identification of N-glycans from Ebola virus glycoproteins by matrix-assisted laser desorption\/ionisation time-of-flight and negative ion electrospray tandem mass spectrometry","volume":"24","author":"Ritchie","year":"2010","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1016\/j.vaccine.2020.08.001_b0070","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/sj.emboj.7600219","article-title":"Ectodomain shedding of the glycoprotein GP of Ebola virus","volume":"23","author":"Dolnik","year":"2004","journal-title":"EMBO J"},{"key":"10.1016\/j.vaccine.2020.08.001_b0075","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1110656","article-title":"Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection","volume":"308","author":"Chandran","year":"2005","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.vaccine.2020.08.001_b0080","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1128\/JVI.80.8.4174-4178.2006","article-title":"Role of endosomal cathepsins in entry mediated by the ebola virus glycoprotein","volume":"80","author":"Schornberg","year":"2006","journal-title":"J Virol"},{"issue":"24","key":"10.1016\/j.vaccine.2020.08.001_b0085","doi-asserted-by":"crossref","first-page":"13378","DOI":"10.1128\/JVI.01170-07","article-title":"Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity","volume":"81","author":"Kaletsky","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.08.001_b0090","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1016\/j.vaccine.2016.06.071","article-title":"Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: standardized template with key considerations for a risk\/benefit","volume":"34","author":"Clarke","year":"2016","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2020.08.001_b0095","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1080\/21645515.2018.1473698","article-title":"The vesicular stomatitis virus-based Ebola virus vaccine: from concept to clinical trials","volume":"14","author":"Suder","year":"2018","journal-title":"Human Vacc Immunotherap"},{"key":"10.1016\/j.vaccine.2020.08.001_b0100","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomized double-blind placebo-controlled phase \u00bd trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.08.001_b0105","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.08.001_b0110","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1016\/j.vaccine.2017.05.097","article-title":"Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic","volume":"35","author":"Coller","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.001_b0115","doi-asserted-by":"crossref","first-page":"7171","DOI":"10.1016\/j.vaccine.2018.09.009","article-title":"Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea","volume":"37","author":"Juan-Giner","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.001_b0120","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus Ebola vaccine","volume":"376","author":"Regules","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2020.08.001_b0125","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1002\/elps.201200095","article-title":"Qualitative and quantitative evaluation of Simon\u2122, A new CE-based automated Western blot system as applied to vaccine development","volume":"33","author":"Rustandi","year":"2012","journal-title":"Electrophoresis"},{"key":"10.1016\/j.vaccine.2020.08.001_b0130","first-page":"197","article-title":"Applications of an Automated and Quantitative CE-based Size and Charge Western Blot for Therapeutic Proteins and Vaccines","volume":"vol. 1466","author":"Rustandi","year":"2006"},{"key":"10.1016\/j.vaccine.2020.08.001_b0135","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ab.2017.06.013","article-title":"Quantitation of CRM197 using imaged capillary isoelectric focusing with fluorescence detection and capillary western","volume":"534","author":"Loughney","year":"2017","journal-title":"Anal Biochem"},{"key":"10.1016\/j.vaccine.2020.08.001_b0140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ab.2014.05.004","article-title":"Residual bovine serum albumin (BSA) quantitation in vaccines using automated Capillary Western technology","volume":"461","author":"Loughney","year":"2014","journal-title":"Anal Biochem"},{"key":"10.1016\/j.vaccine.2020.08.001_b0145","doi-asserted-by":"crossref","unstructured":"Monath TP, East PE, Modjarrad K, Clarke DK, Martin BK, Fusco J, et al. rVSVDG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein:Standardized template with key considerations for a risk\/benefit assessment. Vaccine: X 1 2019;1000009.","DOI":"10.1016\/j.jvacx.2019.100009"},{"issue":"8","key":"10.1016\/j.vaccine.2020.08.001_b0150","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1073\/pnas.93.8.3602","article-title":"The virion glycoprotein of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing","volume":"93","author":"Sanchez","year":"1996","journal-title":"Proc Natl Acad Sci"},{"issue":"Suppl","key":"10.1016\/j.vaccine.2020.08.001_b0155","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.1086\/514280","article-title":"Recombinant human monoclonal antibodies to Ebola virus","volume":"179","author":"Maruyama","year":"1999","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2020.08.001_b0160","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1128\/JVI.00101-16","article-title":"Chimeric filoviruses for identification of monoclonal antibodies","volume":"9","author":"Ilinykh","year":"2016","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2020.08.001_b0165","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies are necessary for rVSV\u0394G-ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates","volume":"110","author":"Marzi","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2020.08.001_b0170","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ebiom.2017.03.045","article-title":"Dose-dependent T-cell dynamics and cytokine cascade following rVSV-ZEBOV immunization","volume":"19","author":"Dahlke","year":"2017","journal-title":"EbioMed"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20310215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20310215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:49:48Z","timestamp":1759402188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20310215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":34,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0264410X20310215"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.08.001","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of rVSV\u0394G-ZEBOV-GP glycoproteins using automated capillary western blotting","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}